Pharma Foods International and NCVC Establish World’s First CADASIL Drug Discovery Research Department

Pharma Foods International Co., Ltd. ( (JP:2929) ) just unveiled an announcement.

Pharma Foods International Co., Ltd. is collaborating with the National Cerebral and Cardiovascular Center to establish the world’s first CADASIL Drug Discovery Research Department, aiming to develop a therapeutic agent for CADASIL, an intractable disease with high unmet medical need. This joint research is expected to advance the development of CADASIL therapeutics, leveraging PFI’s extensive peptide research and contributing to global healthcare by providing effective treatments for patients suffering from this disease.

More about Pharma Foods International Co., Ltd.

Pharma Foods International Co., Ltd. is a company focused on pharmaceutical and dietary research, with a commitment to creating new value in the healthcare field through innovative research and development. They are engaged in the development of therapeutic agents for autoimmune diseases using proprietary technology.

YTD Price Performance: -3.70%

Average Trading Volume: 169,673

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: Yen28.01B

See more insights into 2929 stock on TipRanks’ Stock Analysis page.